JP2013014551A - Composition for virus inactivation - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a safe, low-irritant, and economical composition for virus inactivation exerting excellent inactivation effect with a low concentration in a short time on a non-enveloped virus such as norovirus, on which conventional disinfectants are ineffective.SOLUTION: The composition for virus inactivation includes: one or more selected from the group consisting of polyalkylene biguanide represented by formula (1) and its salts; and one or more of quaternary ammonium salts represented by formula (2). In the formula (1), Ris an alkylene group; and n is an integer of 2-18. In the formula (2), Rand Rare each a 8-18C alkyl group; Rand Rare each a 1-4C alkyl group; and Ais an inorganic or organic anion.

Description

  The present invention relates to a virus inactivating composition having an excellent inactivating effect against viruses such as Norovirus.

In facilities that require daily hygiene management such as food handling facilities, hospitals, and nursing care facilities, the surface of objects such as dishes, cooking utensils, equipment such as medical tools, equipment, and equipment in the facilities should be washed or Various disinfectants are used to disinfect.
Examples of such disinfectants include alcohol preparations such as ethanol for disinfection and isopropanol; halogen compounds such as chlorine preparations such as sodium hypochlorite, iodine preparations such as iodine tincture, compound iodoglycerin and povidone iodine; peroxide preparations such as oxidol; Cationic surfactants such as benzethonium and benzalkonium chloride; amphoteric surfactants such as alkyldiaminoethylglycine; chlorhexidine such as chlorhexidine gluconate; phenols such as phenol and cresol soap; aldehydes such as glutaral and phthalal Is generally used.

  However, among the above-mentioned general-purpose disinfectants, cationic surfactants, amphoteric surfactants, chlorhexidine and phenols have little effect on viruses, and ethanol for disinfection is hepatitis B virus or hepatitis C. It has no effect on viruses. Moreover, the virus inactivation effect is not sufficient even for non-enveloped viruses that cause infection and food poisoning and do not have an envelope. In particular, norovirus infections and food poisoning occur frequently in winter, and food poisoning accounts for about 30% of cases and about 50% of patients, which is a social problem.

  For the inactivation of non-enveloped viruses such as Norovirus, boiling disinfection and the use of sodium hypochlorite are recommended, but boiling disinfection is the heat resistance of the material to be disinfected and increased humidity in the working environment. In some cases, the use of sodium hypochlorite also has a problem of adverse effects such as corrosion on the object to be disinfected. Aldehydes such as glutaral are extremely powerful disinfectants and are effective against viruses, but they are not suitable for the human body, so care must be taken when disinfecting and handling the environment in facilities and rooms. is necessary.

  Under such circumstances, the search for a component that inactivates a non-enveloped virus such as Norovirus is also proceeding, and polyhexamethylene biguanide, especially in the alkaline region, against feline calicivirus of the same Caliciviridae family as Norovirus, It is disclosed that it has an excellent inactivation effect (Patent Document 1).

  Further, quaternary ammonium salts having an alkyl group having a specific chain length belong to caliciviridae, picornaviridae, parvoviridae, papillomaviridae, polyomaviridae, and adenoviridae at pH 5-9. It has been shown to have an inactivating effect on non-enveloped viruses similar to Norovirus, such as viruses (Patent Document 2).

  However, in order to obtain a sufficient inactivation effect with the above-mentioned antiviral component alone, it was necessary to use it at a relatively high concentration or to lengthen the action time. In the disinfecting solution described in Patent Document 1, the content of polyhexamethylene biguanide is required to be 0.05% by weight or more in order to obtain a sufficient inactivation effect against Norovirus, In order to improve the inactivation effect, it is considered preferable to use alcohol in an amount of 40% by weight to 80% by weight. The use of antiviral components and alcohol at high concentrations may have adverse effects such as corrosion on the material of the object to be disinfected, irritation to the skin, etc., and may increase the economic burden. In addition, the non-enveloped virus inactivating agent described in Patent Document 2 requires an action time of 20 minutes in order to obtain a sufficient inactivating effect. If the action time of the antiviral component is long, it is expected that it is often not suitable for practical use. In order to improve such a problem, an attempt has been made to improve the inactivation effect by using an antiviral component in combination, and an amine and / or quaternary ammonium salt and an alkanolamine or a salt thereof have a specific mass. An antiseptic composition containing a ratio has been disclosed (Patent Document 3). However, even in the disinfectant composition described in this document, it cannot be said that the reduction of the concentration of the antiviral component and the shortening of the action time have been sufficiently achieved.

  On the other hand, an antibacterial agent in which an alkylglycoside surfactant and a biguanide compound are used in combination is disclosed (Patent Document 4), but the virus inactivating action is not mentioned at all in this document. Moreover, there is nothing specifically mentioned about the effect show | played when a biguanide type compound, such as polyhexamethylene biguanide, and a quaternary ammonium salt are used together.

JP 2007-045732 A JP 2010-053091 A JP 2005-514427 A JP 2006-143620 A

  Therefore, there are few restrictions on the disinfectable objects that can be used, simple handling, effective for a short time, high safety, low irritation to humans and animals, and economical virus. An inactivating composition is desired. Therefore, the present invention has an excellent inactivating effect against non-enveloped viruses such as Norovirus, which has been ineffective for conventional disinfectants, with a low concentration and a short action, and has high safety and low irritation. It is an object of the present invention to provide a virus inactivating composition that is economical, can be produced at low cost, and is economical.

  As a result of intensive studies to solve the above-mentioned problems, the inventors of the present invention have one or more selected from the group consisting of polyalkylene biguanide compounds such as polyhexamethylene biguanide and salts thereof, and a first chemical compound having a specific chemical structure. It has been found that the combined use with one or more quaternary ammonium salts synergistically improves the inactivation effect on non-enveloped viruses such as norovirus, and the present invention has been completed.

That is, the present invention relates to the following [1] to [11].
[1] One or two or more kinds selected from the group consisting of a polyalkylene biguanide compound represented by formula (1) and a salt thereof, and one or two kinds of quaternary ammonium salts represented by formula (2) The virus inactivation composition containing the above.

[Wherein, R ^a represents an alkylene group having 2 to 8 carbon atoms, and n represents an integer of 2 to 18]. ]

[In the formula, ^{R 1} and ^{R 2} are the same or different, an alkyl group having 8 to 18 carbon atoms, ^{R 3} and ^{R 4} are the same or different and each represents an alkyl group having 1 to 4 carbon atoms, A ^- is an inorganic Or an organic anion is shown. ]

[2] One or more selected from the group consisting of a polyalkylene biguanide compound and a salt thereof and one or more quaternary ammonium salts in a mass ratio of 1: 2 or more The virus inactivating composition according to [1], which is contained as described above.
[3] The above, wherein one or more selected from the group consisting of a polyalkylene biguanide compound and a salt thereof is one or more selected from the group consisting of a polyhexamethylene biguanide and a salt thereof [ The virus inactivating composition according to [1] or [2].
[4] The above [1] to [1], containing one or more selected from the group consisting of a polyalkylene biguanide compound and a salt thereof in a total amount of 0.005% by mass to 0.02% by mass. [3] The virus inactivating composition according to any one of [3].
[5] The virus inactivating composition according to any one of the above [1] to [4], wherein the pH of the composition is 6 to 11.
[6] Any one of [1] to [5] above, wherein one or more quaternary ammonium salts are one or more quaternary ammonium salts represented by formula (3). The virus inactivating composition according to 1.

[Wherein, R ¹ and R ² are the same or different and each represents an alkyl group having 8 to 18 carbon atoms, and A ⁻ represents an inorganic or organic anion. ]

[7] The quaternary ammonium salt according to any one of the above [1] to [6], containing one or more quaternary ammonium salts in a total amount of 0.02% by mass to 0.2% by mass. Virus inactivating composition.
[8] The virus inactivating composition according to any one of the above [1] to [7], wherein the composition is liquid.
[9] The virus inactivating composition according to any one of the above [1] to [8], wherein the virus inactivating composition targets a non-enveloped virus.
[10] A disinfectant containing the virus inactivating composition according to any one of [1] to [7].
[11] A sterilizing detergent containing the virus inactivating composition according to any one of [1] to [7].

  According to the present invention, since a synergistic improvement in virus inactivation effect can be obtained, it has a good virus inactivation effect at a low concentration and in a short time, there are few restrictions on disinfection objects, and safety. In addition, it is possible to obtain a virus inactivating composition that is excellent in handleability and economically advantageous. The virus inactivating composition of the present invention exhibits a particularly excellent inactivating effect against non-enveloped viruses such as Norovirus and is useful as an active ingredient of a disinfectant and a bactericidal detergent.

  The virus inactivating composition of the present invention comprises one or more selected from the group consisting of polyalkylene biguanide compounds and salts thereof, and one or more quaternary ammonium salts. .

  The polyalkylene biguanide compound used in the present invention is represented by the following formula (1).

[Wherein, R ^a represents an alkylene group having 2 to 8 carbon atoms, and n represents an integer of 2 to 18]. ]

In the above formula (1), the alkylene group having 2 to 8 carbon atoms represented by ^Ra includes ethylene, propylene, butylene, pentylene, hexylene (hexamethylene), heptylene (heptamethylene), octylene (octamethylene) and the like. In addition to the linear one, branched chain ones such as isopropylene, isobutylene, isopentylene, dimethylpropylene, dimethylbutylene and the like are included, but a linear alkylene group is preferable. Moreover, from the point of a virus inactivation effect, a C4-C8 alkylene group is preferable and a hexamethylene group is especially preferable. In addition, n in Formula (1) is 2-18, and preferably 10-14, more preferably 11-13, considering the virus inactivation effect, handleability, and the like.

  The polyalkylene biguanide compound represented by the formula (1) can also be used in the form of a salt with an inorganic acid such as hydrochloric acid, nitric acid or sulfuric acid, or a salt with an organic acid such as acetic acid, lactic acid or gluconic acid. Among such salts, hydrochloride, acetate and gluconate are preferable, and hydrochloride is most preferably used. In the virus inactivating composition of the present invention, one or more kinds selected from the group consisting of the polyalkylene biguanide compound represented by the formula (1) and salts thereof are used.

  In the present invention, as the polyalkylene biguanide compound or a salt thereof, a known method, for example, one produced according to the method described in British Patent No. 702,268 or the like can be used. Good. Examples of commercially available products include “Ecline Side BG” (manufactured by Riko Kyosan Co., Ltd.), “Proxel IB” (manufactured by Arch Chemicals), “Lonza Back BG” (manufactured by Lonza Japan Ltd.), and the like.

  In the virus inactivating composition of the present invention, one or two or more selected from the group consisting of the above polyalkylene biguanide compounds and salts thereof are usually 0.001% by mass to 0.1% in total. % By mass, preferably 0.003% by mass to 0.05% by mass, more preferably 0.005% by mass to 0.02% by mass.

  The quaternary ammonium salt used in the present invention is represented by the following formula (2).

[In the formula, ^{R 1} and ^{R 2} are the same or different, an alkyl group having 8 to 18 carbon atoms, ^{R 3} and ^{R 4} are the same or different and each represents an alkyl group having 1 to 4 carbon atoms, A ^- is an inorganic Or an organic anion is shown. ]

In the above formula (2), the alkyl group having 8 to 18 carbon atoms represented by R ¹ or R ² includes octyl, nonyl, decyl, undecyl, dodecyl (lauryl), tetradecyl (myristyl), tetrahexyl (palmityl), Linear alkyl groups such as tetraoctyl (stearyl), 1-methylheptyl (sec-octyl), 6-methylheptyl (isooctyl), 1,1-dimethylhexyl, 2-ethylhexyl, 1-methyltridecyl, 12 -Branched alkyl groups such as methyltridecyl (isomyristyl), 1-methylpentadecyl, 14-methylpentadecyl (isopalmityl), 1-methylheptadecyl, 16-methylheptadecyl (isostearyl) . In Formula (2), examples of the alkyl group having 1 to 4 carbon atoms represented by R ³ or R ⁴ include methyl, ethyl, propyl, 2-propyl (isopropyl), butyl, 1-methylpropyl (sec-butyl) ), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl).

A quaternary ammonium salt represented by the following formula (3) in which R ³ and R ⁴ in the above formula (2) are both methyl is preferable from the viewpoint of virus inactivation effect and the like. Further, among the quaternary ammonium salts represented by the formula (3), a didecyldimethylammonium salt is particularly preferable.

In the above formula (2), examples of the inorganic or organic anion represented by A ⁻ include halogen ions, inorganic acid ions, and organic acid ions.
Examples of the halogen ion include chlorine ion, bromine ion and iodine ion. Examples of inorganic acid ions include nitrate ions, sulfate ions, phosphate ions, and the like. Examples of organic acid ions include alkyl sulfate ester ions having about 1 to 3 carbon atoms such as methyl sulfate ions; monocarboxylic acid ions having about 2 to 6 carbon atoms such as acetate ions, propionate ions, butyrate ions, and caproate ions; Hydroxycarboxylic acid ions having about 3 to 6 carbon atoms such as lactate ion, malate ion and citrate ion; carbon such as oxalate ion, malonate ion, succinate ion, fumarate ion, maleate ion and adipate ion Examples thereof include dicarboxylic acid ions of about 2 to 6.
Of these, halogen ions, sulfate ions, alkyl sulfate ester ions, and dicarboxylate ions are preferable, and chloride ions and adipate ions are particularly preferable.

  In the virus inactivating composition of the present invention, one or more kinds selected from the quaternary ammonium salt represented by the above formula (2) are used. Such a quaternary ammonium salt can be produced and used according to a known method. However, “Cotamine D10P”, “Cotamine D86P”, “Cotamine D2345P” (manufactured by Kao Corporation), “Burduck 2280/2250”, “Kobo Quart” (manufactured by Lonza Japan Co., Ltd.), “Cathogen DDM-PG” (manufactured by Daiichi Kogyo Seiyaku Co., Ltd.), “Cation DDC-50”, “Osmolin DA-50” (manufactured by Sanyo Chemical Industries, Ltd.) (Commercially available products) can also be used.

  In the virus inactivating composition of the present invention, one or more kinds selected from the quaternary ammonium salts are generally 0.002% by mass to 0.5% by mass, preferably 0 in terms of the total amount thereof. 0.02 mass% to 0.2 mass%, more preferably 0.04 mass% to 0.1 mass%.

  In the virus inactivating composition of the present invention, one or more selected from the group consisting of a polyalkylene biguanide compound represented by the formula (1) and a salt thereof, and a quaternary represented by the formula (2) One or two or more selected from ammonium salts are preferably contained so that the mass ratio is 1: 2 or more, and more preferably 1: 4 or more. By containing these at such a mass ratio, a better virus inactivating effect can be obtained. The improvement in virus inactivation effect becomes more significant as the ratio of the quaternary ammonium salt content to the polyalkylene biguanide compound and / or its salt content increases. Then, it is preferable to set it as 1:20 or less, and it is more preferable to set it as 1:15 or less.

  In particular, considering the inactivation effect and handleability of non-enveloped viruses such as Norovirus, the pH of the virus inactivating composition of the present invention is preferably 6 to 11, and preferably 6.5 to 10 Is more preferable, and 9 to 10 is particularly preferable. The pH of the composition can be adjusted by a conventional method using a buffer or a pH adjuster as appropriate. Examples of the buffer include citrate-phosphate buffer, phosphate buffer, tris (hydroxymethyl) aminomethane-hydrochloric acid buffer, glycine-sodium hydroxide buffer, and the like. Citric acid, gluconic acid, succinic acid, potassium carbonate, sodium hydrogen carbonate, sodium hydroxide and the like can be mentioned.

  In addition to the polyalkylene biguanide compound and / or salt thereof, and quaternary ammonium salt, the virus inactivating composition of the present invention includes general antiviruses such as acyclovir as long as the characteristics of the present invention are not impaired. Common antibacterial components such as components, phenoxyethanol, chlorhexidine gluconate, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, and alkyldiaminoethylglycine hydrochloride can also be contained.

  The virus inactivating composition of the present invention can be provided in various forms such as liquid, paste, gel, milk, solid using a liquid carrier, a gel carrier, an emulsion, a solid carrier and the like. In order to act on a wide range of objects to be disinfected in a short time, it is preferable to use a liquid composition. Examples of liquid carriers include water; lower alcohols such as ethanol, isopropanol, and butanol; and organic solvents such as polyhydric alcohols such as ethylene glycol, propylene glycol, glycerin, and butylene glycol. In view of handling property and economic efficiency, it is preferable to use water or a mixture of water and the organic solvent.

  Furthermore, the virus inactivating composition of the present invention includes the above quaternary ammonium salt for the purpose of imparting detergency and foaming properties within the range that does not affect the inactivating effect against viruses or the stability of the composition. Surfactants other than can be added. Examples of such surfactants include other cationic surfactants such as primary to tertiary fatty amine salts, 2-alkyl-1-alkyl-1-hydroxyethylimidazolinium salts; N, N— Alkyl betaine types such as dimethyl-N-alkyl-N-carboxymethylammonium betaine, aminocarboxylic acid types such as N, N-dialkylaminoalkylene carboxylic acid, N, N, N-trialkyl-N-sulfoalkylene ammonium betaine, etc. And imidazoline type amphoteric surfactants such as 2-alkyl-1-hydroxyethyl-1-carboxymethylimidazolinium betaine can be used. Water-soluble polymers such as gum arabic, carrageenan, sodium carboxymethylcellulose, hydroxycellulose, sodium polyacrylate, etc. for the purpose of increasing foam, improving formulation stability, coloring, flavoring, etc .; sodium ethylenediaminetetraacetate, tripolyphosphoric acid Sequestering agents such as hexametaphosphate; inorganic salts such as sodium chloride, potassium chloride and sodium sulfate; dyes; fragrances and the like.

The virus inactivating composition of the present invention comprises a group I double stranded DNA virus, a group II single stranded DNA virus, a group III double stranded RNA virus, a group IV single stranded RNA + strand virus, and a group V. Inactivation effect is not particularly limited for all viruses of single-strand RNA-strand virus, group VI single-strand RNA virus + strand reverse transcription virus, and group VII double-strand DNA reverse transcription virus. Show a good inactivation effect against non-enveloped viruses. Examples of such non-enveloped viruses include Norovirus such as Norwalk virus (NV), Sapovirus such as Sapporo virus (SV), and Rabbit hemorrhagic disease. Lacivirus (Lagovirus) such as virus), Feline calicivirus, Caliciviridae virus such as Vesivirus such as Swine vesicular exanthema virus; Poliovirus (Poliovirus) Poliovirus), Coxsackievirus, Echovirus, Enterovirus such as Enterovirus, Rhinovirus such as common cold virus, Hepatitis A virus ) Hepatovirus (Hepatovirus), human Parechoviruses such as human parechoviruses, Kobuviruses such as Aichi virus, and foot-and-mouth disease viruses such as foot-and-mouth disease viruses (Aohthovirus) Picornaviridae viruses such as); Erythroviruses such as Parvovirus B19 (Parvovirus B19), Bocaviruses such as Human Bocavirus (HBoV), adeno-associated viruses ( Dependovirus such as Adeno-associated virus, Parsoviridae virus such as Dependovirus, Densovirus, Aedes aegypti densovirus (AaDNV); Human papillomavirus: HPV), bovine papillomavirus (BPV), rabbit papillomavirus ( Papillomaviridae viruses such as Genus papillomavirus such as Cottontail rabbit papillomavirus (CRPV); JC polyomavirus (Polyomavirus JC), BK polyomavirus (Polyomavirus BK), African green monkey polyoma virus (African) polyomaviridae viruses such as polymonomavirus (green monkey polyomavirus: AGMPyV), Simian virus 40 (SV-40), etc .; human adenovirus, bovine adenovirus (Bovine adenovirus), adenoviridae viruses such as mastadenovirus such as porcine adenovirus.
The virus inactivating composition of the present invention is excellent in inactivating effect against Caliciviridae virus, and is excellent in inactivating effect on viruses belonging to the genus Norovirus and Sapovirus among the Caliciviridae viruses, particularly in the genus Norovirus. Excellent inactivation effect against the virus to which it belongs.

  In the present invention, the “virus inactivating composition” refers to a composition that removes or reduces the infectivity or proliferation ability of the virus described above. Therefore, it is not always necessary to have the action of denaturing or disrupting virus particles or nucleic acids, and the ability of the virus to infect the host cell or the like through adsorption to the surface of the virus or host cell, binding to the enzyme of the virus, etc. Any substance that can reduce or inhibit the ability to grow in a host cell may be used.

  The virus inactivating composition of the present invention can be used as a disinfectant or a disinfectant cleaning agent as it is or by adding various carriers, other surfactants, disinfectants and the like. The disinfectant or disinfectant cleaning agent of the present invention can be provided in various forms such as liquid, gel, powder, etc., but in order to act on a wide range of disinfecting objects in a short time, it may be liquid. preferable. Liquid disinfectants or disinfectants can be provided as lotions, sprays, etc., filled into bottles with measuring caps, trigger type spray containers, squeeze type or dispenser type pump spray containers, etc. It can be used by spraying.

  The disinfectant or disinfectant cleaning agent of the present invention can be used for disinfecting, disinfecting and washing in facilities such as hospital rooms, living rooms, cooking rooms, bathrooms, toilets, toilets, furniture such as tables, chairs, bedding, tableware, cooking utensils, medical It can be widely used for disinfection, sterilization cleaning, etc. of places where viruses may exist or items that may be contaminated with viruses, such as disinfection, sterilization cleaning, etc. .

  The disinfectant or disinfectant cleaning agent of the present invention may be used in such an amount that the surface of the object to be disinfected is evenly wetted. Further, the action time of the disinfectant or sterilizing cleaning agent of the present invention on the object to be disinfected can be short, and a sufficient disinfecting or sterilizing cleaning effect can be obtained in 3 to 5 minutes.

  Hereinafter, the present invention will be described in more detail with reference to examples. In the following, “%” means mass% unless otherwise specified.

[Examples 1 to 3, Comparative Examples 1 to 5]
Each component shown in Table 1 was sequentially added and dissolved in ion-exchanged water to prepare each virus inactivating composition of Examples 1 to 3 and Comparative Examples 1 to 4. In addition, pH of these compositions was 9-10 with the glycine-sodium hydroxide buffer. Comparative Example 5 is a composition containing only the buffer solution.

[Evaluation of norovirus inactivation effect]
Since norovirus itself cannot be cultured for evaluation of the inactivating effect on norovirus, as an alternative, viral infection using a feline calicivirus (hereinafter referred to as “FCV”) belonging to the same Caliciviridae family as norovirus is used. Evaluation was made by measuring the value.
That is, FCV-F9 strain was used as a test virus. In addition, as a host cell, a feline kidney-derived cell line (CRFK cell) adjusted to 2 × 10 ⁵ cells / mL with 1% fetal calf serum-added minimum essential medium (MEM (F1)) was added to each of the 96-well microplates. A 0.1 mL aliquot was dispensed into each well and cultured overnight under conditions of 36 ° C. and 5% CO ₂ to obtain monolayer cultured cells.

[Measurement of infectious titer]
As a test virus solution, the FCV-F9 strain is adjusted to 4-6 as the following log ₁₀ TCID ₅₀ by a mixed solution of phosphate buffered saline (PBS) and MEM (F1) in a volume ratio of 9: 1. The suspension prepared above was used.
Take 0.5 mL of each composition of Examples 1 to 3 and Comparative Examples 1 to 5 as a test solution, add 0.5 mL of the test virus solution to this and sensitize for 5 minutes at room temperature. 0.1 mL was added to 0.9 mL of MEM (F1), and 10-fold serial dilution was performed. 0.1 ml of this serial dilution was inoculated into 4 wells and cultured under conditions of 36 ° C. and 5% CO ₂ for 7 days.
After culture, the presence or absence of cytopathic appearance was determined, and the virus infectivity titer (TCID ₅₀ /0.1 mL) was calculated by the Reed-Munch method. The virus inactivation effect was evaluated for each test solution by the difference (Δlog ₁₀ TCID ₅₀ /0.1 mL) from the infectivity titer when measured using PBS as a control.

  About the virus inactivation composition of Examples 1-3 and Comparative Examples 1-5, the evaluation result of the norovirus inactivation effect was combined with Table 1, and was shown.

In this evaluation of the norovirus inactivation effect, when an increase of 1 or more was observed in the Δlog ₁₀ TCID ₅₀ /0.1 mL value, that is, when the virus infectivity titer was 1/10 or less, the virus inactivation effect It was judged that a synergistic improvement was recognized. In Table 1, in each virus inactivation composition of Examples 1-3 which used together 0.01 mass% polyhexamethylene biguanide hydrochloride and 0.02-0.04 mass% didecyldimethylammonium chloride, Compared with each composition of Comparative Examples 1 to 4 containing hexamethylene biguanide hydrochloride or didecyldimethylammonium chloride alone, the Δlog ₁₀ TCID ₅₀ /0.1 mL value increased by 1.7 or more, and polyhexamethylene By using biguanide hydrochloride and didecyldimethylammonium chloride in combination, a synergistic improvement in virus inactivation effect was observed.

[Examples 4 and 5 and Comparative Examples 6 to 9]
The components shown in Table 2 were sequentially added and dissolved in ion-exchanged water to prepare virus inactivating compositions of Examples 4, 5 and Comparative Examples 6-8. In addition, pH of these compositions was 6-7 with the phosphate buffer solution. Comparative Example 9 is a composition containing only the buffer solution.

  About each composition of Example 4, 5 and Comparative Examples 6-9, the norovirus inactivation effect was evaluated similarly to the above. The evaluation results are also shown in Table 2.

In Table 2, in the virus inactivating composition of Example 4 or 5 using 0.01% by mass of polyhexamethylene biguanide hydrochloride and 0.04% by mass or 0.1% by mass of didecyldimethylammonium chloride, Compared to each composition of Comparative Examples 6 to 8 containing 0.01% by mass of polyhexamethylene biguanide hydrochloride or 0.04% by mass or 0.1% by mass of didecyldimethylammonium chloride, respectively, Δlog ₁₀ TCID _{The 50 /} 0.1 mL value increased by 0.9 or 1.0, and a synergistic improvement in the virus inactivation effect was observed by using polyhexamethylene biguanide hydrochloride and didecyldimethylammonium chloride in combination. It was.

[Example 6, Comparative Examples 10-15]
The components shown in Table 3 were sequentially added to and dissolved in ion-exchanged water to prepare virus inactivating compositions of Example 6 and Comparative Examples 10-15. In addition, pH of these compositions was 9-10 with the glycine-sodium hydroxide buffer.

  About each virus inactivation composition of Example 6 and Comparative Examples 10-15, the norovirus inactivation effect was evaluated similarly to the above. The evaluation results are also shown in Table 3.

  In Table 3, in the virus inactivating composition of Example 6 containing 0.01% by mass of polyhexamethylene biguanide hydrochloride and 0.1% by mass of didecyldimethylammonium adipate, polyhexamethylene biguanide hydrochloride As compared with the virus inactivating composition of Comparative Example 15 containing only 0.01% by mass of salt, a significant increase in virus inactivating effect was observed. However, in place of didecyldimethylammonium adipate, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, octyldimethyl which are quaternary ammonium salts not corresponding to the quaternary ammonium salt represented by the above formula (2) In each composition of Comparative Examples 10 to 14 using ethylammonium sulfate or lauryldimethylethylammonium sulfate, such an improvement in virus inactivating effect was not observed.

  As described above in detail, the present invention has an effective virus inactivating effect with a low concentration and a short action, has few restrictions on the object to be disinfected, is excellent in safety and handleability, and is economically advantageous. Thus, it is possible to provide a virus inactivating composition useful as an active ingredient of a disinfectant and a bactericidal cleaning agent. The virus inactivating composition of the present invention is a particularly useful composition for non-enveloped viruses such as Norovirus.

Claims (11)

One or more selected from the group consisting of a polyalkylene biguanide compound represented by formula (1) and a salt thereof, and one or more quaternary ammonium salts represented by formula (2) A virus inactivating composition comprising:
[Wherein, R ^a represents an alkylene group having 2 to 8 carbon atoms, and n represents an integer of 2 to 18]. ]
[In the formula, ^{R 1} and ^{R 2} are the same or different, an alkyl group having 8 to 18 carbon atoms, ^{R 3} and ^{R 4} are the same or different and each represents an alkyl group having 1 to 4 carbon atoms, A ^- is an inorganic Or an organic anion is shown. ]   1 type or 2 or more types selected from the group consisting of a polyalkylene biguanide compound and a salt thereof and 1 type or 2 or more types of quaternary ammonium salts are contained so that the mass ratio is 1: 2 or more The virus inactivating composition according to claim 1.   The 1 type (s) or 2 or more types selected from the group which consists of a polyalkylene biguanide compound and its salt are 1 type (s) or 2 or more types selected from the group which consists of a polyhexamethylene biguanide and its salt. The virus inactivating composition according to 1.   1 type or 2 types or more selected from the group which consists of a polyalkylene biguanide compound and its salt are contained in 0.005 mass%-0.02 mass% of these total amounts, Any 1 of Claims 1-3 The virus inactivating composition according to Item.   The virus inactivating composition according to any one of claims 1 to 4, wherein the pH of the composition is 6 to 11. The virus according to any one of claims 1 to 5, wherein one or more quaternary ammonium salts are one or more quaternary ammonium salts represented by formula (3). Inactivated composition.
[Wherein, R ¹ and R ² are the same or different and each represents an alkyl group having 8 to 18 carbon atoms, and A ⁻ represents an inorganic or organic anion. ]   The virus inactivating composition according to any one of claims 1 to 6, comprising 0.02% by mass to 0.2% by mass of one or more quaternary ammonium salts as a total amount thereof. object.   The virus inactivating composition according to any one of claims 1 to 7, wherein the composition is liquid.   The virus inactivating composition according to any one of claims 1 to 8, wherein the virus inactivating composition is for a non-enveloped virus.   A disinfectant containing the virus inactivating composition according to any one of claims 1 to 7.   A sterilizing detergent containing the virus inactivating composition according to any one of claims 1 to 7.